New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
